Clinical trial
A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia Vera
NCT07859423 is registered in ClinicalTrials.gov with Agios Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia Vera
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- August 31, 2032
- Enrollment
- 245 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.